Literature DB >> 15803934

Mycophenolate mofetil in systemic vasculitis.

D P D'Cruz1.   

Abstract

The systemic vasculitides are a group of potentially life-threatening multi-system autoimmune connective tissue diseases characterized by vascular inflammation. The gold standard therapies include corticosteroids and cyclophosphamide as induction therapy and other agents such as azathioprine and methotrexate to maintain remission. Mycophenolate mofetil (MMF) is increasingly being used in autoimmune disorders and this article reviews the use of this agent in the systemic vasculitides.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15803934     DOI: 10.1191/0961203305lu2120oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  2 in total

1.  Mycophenolate mofetil in the treatment of uveitis in children.

Authors:  D Doycheva; C Deuter; N Stuebiger; S Biester; M Zierhut
Journal:  Br J Ophthalmol       Date:  2006-07-06       Impact factor: 4.638

2.  Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome.

Authors:  Kamran Afzal; Arvind Bagga; Shina Menon; Pankaj Hari; Stanley C Jordan
Journal:  Pediatr Nephrol       Date:  2007-10-16       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.